CN105658221B - 用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物 - Google Patents

用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物 Download PDF

Info

Publication number
CN105658221B
CN105658221B CN201480053306.1A CN201480053306A CN105658221B CN 105658221 B CN105658221 B CN 105658221B CN 201480053306 A CN201480053306 A CN 201480053306A CN 105658221 B CN105658221 B CN 105658221B
Authority
CN
China
Prior art keywords
pharmaceutical composition
atrophic
skin
scarring
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480053306.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN105658221A (zh
Inventor
沃伦·J·舍雷尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma SA filed Critical Galderma SA
Publication of CN105658221A publication Critical patent/CN105658221A/zh
Application granted granted Critical
Publication of CN105658221B publication Critical patent/CN105658221B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
  • External Artificial Organs (AREA)
CN201480053306.1A 2013-09-26 2014-09-26 用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物 Expired - Fee Related CN105658221B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361960740P 2013-09-26 2013-09-26
US61/960,740 2013-09-26
PCT/IB2014/002746 WO2015044788A1 (en) 2013-09-26 2014-09-26 Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring

Publications (2)

Publication Number Publication Date
CN105658221A CN105658221A (zh) 2016-06-08
CN105658221B true CN105658221B (zh) 2022-05-10

Family

ID=52282772

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480053306.1A Expired - Fee Related CN105658221B (zh) 2013-09-26 2014-09-26 用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物

Country Status (11)

Country Link
US (1) US10039770B2 (enExample)
EP (1) EP3049088B1 (enExample)
JP (1) JP6453318B2 (enExample)
KR (1) KR102221499B1 (enExample)
CN (1) CN105658221B (enExample)
AU (1) AU2014326298B2 (enExample)
BR (1) BR112016006426A2 (enExample)
CA (1) CA2924460A1 (enExample)
MX (1) MX374476B (enExample)
RU (1) RU2690183C2 (enExample)
WO (1) WO2015044788A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6659819B2 (ja) * 2015-07-09 2020-03-04 ガルデルマ・ソシエテ・アノニム 化学療法に関連する脱毛の軽減方法
CN106929477B (zh) * 2017-03-20 2020-01-10 江南大学 一株抗前列腺素F2α的特异性单克隆抗体杂交瘤细胞株WXX-2及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
RU2195889C2 (ru) * 1999-05-24 2003-01-10 Парамонов Борис Алексеевич Способ дермабразии
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
EP2278993A4 (en) * 2008-05-16 2012-09-12 Corthera Inc METHOD FOR PROMOTING HEALING
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
CN102031260A (zh) * 2010-08-24 2011-04-27 苏州圣诺生物医药技术有限公司 促进皮肤伤口无疤痕愈合的siRNA及应用
EP3178465A1 (en) * 2010-12-06 2017-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
AU2012212481A1 (en) * 2011-01-31 2013-08-22 Allergan, Inc. Method of enhancing hair growth
US20120251613A1 (en) * 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue
WO2014179263A1 (en) * 2013-04-30 2014-11-06 Allergan, Inc. Therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Repigmentation of Hypopigmented Scars Using an Erbium-Doped 1,550-nm Fractionated Laser and Topical Bimatoprost;ANE BEATRIZ MAUTARI NIWA MASSAKI等;《DERMATOLOGIC SURGERY》;20121231;第38卷;第995–1001页 *

Also Published As

Publication number Publication date
JP6453318B2 (ja) 2019-01-16
CN105658221A (zh) 2016-06-08
KR102221499B1 (ko) 2021-03-02
RU2016110925A (ru) 2017-11-01
AU2014326298A1 (en) 2016-04-07
MX2016003650A (es) 2016-06-24
WO2015044788A1 (en) 2015-04-02
US10039770B2 (en) 2018-08-07
EP3049088A1 (en) 2016-08-03
RU2016110925A3 (enExample) 2018-07-13
EP3049088B1 (en) 2021-02-17
RU2690183C2 (ru) 2019-05-31
KR20160055941A (ko) 2016-05-18
US20160228453A1 (en) 2016-08-11
AU2014326298B2 (en) 2019-07-04
MX374476B (es) 2025-03-06
JP2016531872A (ja) 2016-10-13
CA2924460A1 (en) 2015-04-02
BR112016006426A2 (pt) 2017-08-01

Similar Documents

Publication Publication Date Title
JP5580210B2 (ja) 手術前治療
KR101420599B1 (ko) 항여드름제를 함유하는 조성물 및 이의 용도
US20020054896A1 (en) Method and composition for the treatment of scars
RU2587041C2 (ru) Способ предотвращения или лечения опухоли кожи
JP7421558B2 (ja) 組織修復に適用されるピルフェニドンを含有する半固体油性医薬組成物
US20200012989A1 (en) Compositions and methods for treating cutaneous conditions
JP2024144774A (ja) 化粧品/皮膚科用組成物
JP2014518239A (ja) 皮膚反応を低減するための新規な安定麻酔組成物
HK1220637A1 (zh) 治疗皮肤增厚的方法
EP2994120B1 (en) Alpha adrenergic agonists for the treatment of tissue trauma
CN105658221B (zh) 用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物
US20190000936A1 (en) Prophylactic normalization of cutaneous wound repair
US20170281690A1 (en) Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis
JP2014530847A (ja) 毛細血管腫の治療方法
KR101917026B1 (ko) 피부 주름 개선 또는 예방용 화장료 조성물
CN117651553A (zh) 用于治疗萎缩性瘢痕的犬尿氨酸及其衍生物
Brocario et al. Assessment of wound healing efficacy and tolerability using Cicatryl™ cream based on a suction blister model in healthy subjects
DE202018000489U1 (de) Hautpflegeprodukt zur Behandlung frischer und alter Narben

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220510

CF01 Termination of patent right due to non-payment of annual fee